Newly redesigned Flexitron brachytherapy afterloading platform to be introduced at ABS meeting

At the 2013 American Brachytherapy Society (ABS) meeting April 18-20 in New Orleans, Nucletron, an Elekta company, (booth #300), will introduce its newly redesigned Flexitron® remote afterloading platform. Flexitron emphasizes safety and efficiency in the brachytherapy workflow, increasing the clinician's confidence that execution of all workflow steps will proceed as planned for brachytherapy / treatment delivery.

Key to the new Flexitron are multiple advances that optimize the treatment delivery process. One of these features is an intuitive layout that efficiently leads the user through the treatment delivery workflow. Flexitron also includes transfer tubes that all are of the same 1000 mm length, reducing ambiguity; a "reference zero" at the entrance of the catheter; a dwell position number that directly reflects the dwell position distance; and forward stepping source positioning.

Flexitron features scalable configurations with 10, 20 or 40 channels and is compatible with Nucletron applicators, Oncentra® Brachy and the HDR Real-Time Prostate Solution.

"We are very pleased to introduce the new Flexitron afterloading platform to the North American market," says Maurits Wolleswinkel , VP Business Line Management, for Elekta's brachytherapy business area. "We believe Flexitron afterloading is revolutionizing safety and workflow in the modern brachytherapy practice, and since it is designed around an upgradable architecture, Flexitron represents a truly safe investment for the future."

In addition to the newly released Flexitron, Elekta showcased the depth and breadth of its brachytherapy solutions, including Oncentra Brachy planning system, a fully developed line of body site specific applicators, and dedicated Real Time Prostate Solutions. 

SOURCE Elekta

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Elekta. (2023, September 12). Newly redesigned Flexitron brachytherapy afterloading platform to be introduced at ABS meeting. News-Medical. Retrieved on December 22, 2024 from https://www.news-medical.net/news/20130419/Newly-redesigned-Flexitron-brachytherapy-afterloading-platform-to-be-introduced-at-ABS-meeting.aspx.

  • MLA

    Elekta. "Newly redesigned Flexitron brachytherapy afterloading platform to be introduced at ABS meeting". News-Medical. 22 December 2024. <https://www.news-medical.net/news/20130419/Newly-redesigned-Flexitron-brachytherapy-afterloading-platform-to-be-introduced-at-ABS-meeting.aspx>.

  • Chicago

    Elekta. "Newly redesigned Flexitron brachytherapy afterloading platform to be introduced at ABS meeting". News-Medical. https://www.news-medical.net/news/20130419/Newly-redesigned-Flexitron-brachytherapy-afterloading-platform-to-be-introduced-at-ABS-meeting.aspx. (accessed December 22, 2024).

  • Harvard

    Elekta. 2023. Newly redesigned Flexitron brachytherapy afterloading platform to be introduced at ABS meeting. News-Medical, viewed 22 December 2024, https://www.news-medical.net/news/20130419/Newly-redesigned-Flexitron-brachytherapy-afterloading-platform-to-be-introduced-at-ABS-meeting.aspx.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Spinal cord stimulation may help reduce chronic pain in people undergoing active cancer treatment